There is no single “best” medication for sleep apnea because the condition is primarily treated with devices, not drugs. CPAP (continuous positive airway pressure) remains the gold standard. However, the FDA approved the first medication specifically for obstructive sleep apnea in 2024, and several other drugs play supporting roles depending on what type of sleep apnea you have and which symptoms persist after other treatments.
The medication landscape for sleep apnea breaks into three categories: drugs that treat the condition itself, drugs that manage leftover daytime sleepiness, and drugs used off-label for specific situations. Here’s what works, what’s new, and what to realistically expect.
The First FDA-Approved Sleep Apnea Drug
In 2024, the FDA approved tirzepatide (brand name Zepbound) as the first medication specifically indicated for moderate to severe obstructive sleep apnea in adults with obesity. It works by mimicking gut hormones that reduce appetite and promote significant weight loss, which in turn shrinks the fatty tissue around the airway that contributes to obstruction during sleep.
The approval came from two randomized, placebo-controlled trials involving 469 adults. Participants who took weekly injections for 52 weeks saw a median reduction of up to 63% in their apnea-hypopnea index, the standard measure of how many times per hour breathing is disrupted during sleep. That’s a substantial improvement, though the drug must be combined with a reduced-calorie diet and increased physical activity. It also only applies to people whose sleep apnea is linked to obesity, so it won’t help everyone with the condition.
This is the same drug already approved for type 2 diabetes and weight management under different brand names. If you’re carrying significant extra weight and your sleep apnea is moderate to severe, this represents a genuine new option. But it requires ongoing weekly injections, and stopping the medication typically means regaining weight and losing the breathing benefits.
Medications for Daytime Sleepiness
Many people with sleep apnea still feel excessively sleepy during the day even after using CPAP consistently. For this specific problem, two medications are commonly prescribed.
Solriamfetol (Sunosi) is a wake-promoting agent that increases alertness without treating the underlying airway obstruction. The typical starting dose is 37.5 mg once daily, which your doctor can increase up to 150 mg. It works by boosting dopamine and norepinephrine activity in the brain. The main concerns are increases in blood pressure and heart rate, along with potential psychiatric symptoms. If you already have cardiovascular issues, this needs careful monitoring.
Pitolisant (Wakix) takes a different approach, working through histamine pathways in the brain to promote wakefulness. The most common side effects are headache, insomnia, and nausea. One important safety consideration: pitolisant can prolong the QT interval on an EKG, which affects heart rhythm. It should be avoided if you already have a prolonged QT interval or take other medications that affect heart rhythm. It’s also not suitable for people with severe liver disease.
Older options like modafinil and armodafinil are also prescribed for residual sleepiness. They carry warnings for rare but serious skin reactions and allergic responses, and people with cardiovascular disease need extra monitoring due to an increase in cardiac events. Stimulants like methylphenidate are occasionally used but carry addiction risk and can raise blood pressure and heart rate.
None of these medications replace CPAP or treat the breathing interruptions themselves. They’re add-ons for the sleepiness that persists despite using your primary treatment.
Off-Label Options for Central Sleep Apnea
Central sleep apnea is a different condition from the more common obstructive type. Instead of a physical blockage, the brain intermittently fails to send proper signals to the breathing muscles. Medication plays a slightly larger role here because the problem is neurological rather than mechanical.
Acetazolamide, a drug originally developed for altitude sickness and glaucoma, is sometimes used off-label to stabilize breathing patterns during sleep. It works by making the blood slightly more acidic, which stimulates the brain’s respiratory drive and makes breathing pauses less likely. Doses in studies have ranged widely, from 36 mg to 1,000 mg per day, with higher doses (up to 500 mg daily) showing greater reductions in breathing disruptions. This is not FDA-approved for sleep apnea and is typically reserved for specific subtypes of central sleep apnea.
Drugs That Don’t Work (Yet)
You may come across mentions of cannabis-based treatments for sleep apnea, particularly dronabinol, a synthetic cannabis extract. A few small pilot studies suggested it might improve respiratory stability, but the evidence is thin. Most patients in those studies experienced significant drowsiness as a side effect, and long-term safety data doesn’t exist. The American Academy of Sleep Medicine has taken a clear stance: medical cannabis and its synthetic extracts should not be used for sleep apnea. They’ve even recommended that sleep apnea be excluded from qualifying conditions for state medical cannabis programs.
A combination of atomoxetine and oxybutynin is another approach generating interest. The idea is to boost the activity of the muscles that hold the airway open during sleep. This combination is still in early clinical trials (Phase 1/2) and is not available as a standard treatment. Researchers are trying to figure out which patients would respond best based on the specific physical traits causing their airway collapse.
Why CPAP Still Comes First
The reason no medication has replaced CPAP is straightforward: obstructive sleep apnea is a structural problem. Tissue collapses into the airway during sleep, and air pressure is the most reliable way to keep it open. Medications can chip away at contributing factors like excess weight or residual sleepiness, but they don’t physically splint the airway the way pressurized air does.
For people who genuinely cannot tolerate CPAP, oral appliances that reposition the jaw are the next-line option, followed by surgical procedures in select cases. Medications occupy a supporting role: tirzepatide for weight-driven cases, wake-promoting agents for persistent sleepiness, and acetazolamide for certain central sleep apnea patterns.
The most effective approach for most people combines consistent CPAP use with weight management and positional strategies (like avoiding sleeping on your back). If you’re looking for a pill to replace your CPAP machine entirely, that option doesn’t exist yet. But if you’re dealing with specific symptoms that CPAP alone isn’t solving, the medication options above offer real, targeted help.